| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $36,574,794 | 22 | 100 |
| Garfield Alastair | Chief Scientific Officer | 0 | $0 | 1 | $912,703 | $-912,703 |
| German Christopher Paul | Corporate Controller & CAO | 0 | $0 | 2 | $930,921 | $-930,921 |
| Cramer Pamela J. | Chief Human Resources Officer | 0 | $0 | 4 | $2.99M | $-2.99M |
| Shulman Joseph | Chief Technical Officer | 0 | $0 | 4 | $3.67M | $-3.67M |
| TETRAULT LYNN A. | director | 0 | $0 | 1 | $3.71M | $-3.71M |
| Mazabraud Yann | EVP, Head of International | 0 | $0 | 1 | $6.62M | $-6.62M |
| Smith Hunter C | Chief Financial Officer | 0 | $0 | 8 | $8.84M | $-8.84M |
| Lee Jennifer Kayden | EVP, Head of North America | 0 | $0 | 1 | $8.9M | $-8.9M |
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Over the last 12 months, insiders at Rhythm Pharmaceuticals, Inc. have bought $0 and sold $36.57M worth of Rhythm Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Rhythm Pharmaceuticals, Inc. have bought $0 and sold $19.63M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $201,713 was made by Meeker David P (President and CEO) on 2021‑03‑30.
| 2026-08-31 | Sale | Smith Hunter C | Chief Financial Officer | 62,774 0.0909% | $105.46 | $6.62M | -1.24% | |
| 2026-08-13 | Sale | Shulman Joseph | Chief Technical Officer | 5,079 0.0076% | $119.75 | $608,210 | -4.57% | |
| 2026-08-13 | Sale | Garfield Alastair | Chief Scientific Officer | 7,763 0.0115% | $117.57 | $912,703 | -4.57% | |
| 2026-08-13 | Sale | Lee Jennifer Kayden | EVP, Head of North America | 75,834 0.1119% | $117.38 | $8.9M | -4.57% | |
| 2026-08-12 | Sale | Mazabraud Yann | EVP, Head of International | 57,000 0.0821% | $116.15 | $6.62M | -5.24% | |
| 2026-06-22 | Sale | TETRAULT LYNN A. | director | 37,000 0.0534% | $100.32 | $3.71M | +8.19% | |
| 2026-05-15 | Sale | German Christopher Paul | Corporate Controller & CAO | 4,643 0.0069% | $92.21 | $428,131 | +17.24% | |
| 2026-03-04 | Sale | German Christopher Paul | Corporate Controller & CAO | 5,614 0.0083% | $89.56 | $502,790 | +2.19% | |
| 2026-02-19 | Sale | Smith Hunter C | Chief Financial Officer | 4,385 0.0066% | $101.26 | $444,004 | -9.84% | |
| 2026-02-17 | Sale | Smith Hunter C | Chief Financial Officer | 3,569 0.0053% | $101.38 | $361,810 | -8.79% | |
| 2026-02-12 | Sale | Smith Hunter C | Chief Financial Officer | 1,592 0.0024% | $98.23 | $156,380 | -2.53% | |
| 2026-02-11 | Sale | Smith Hunter C | Chief Financial Officer | 2,766 0.0042% | $98.61 | $272,766 | -4.87% | |
| 2026-02-10 | Sale | Smith Hunter C | Chief Financial Officer | 2,713 0.0041% | $103.00 | $279,429 | -8.89% | |
| 2026-02-05 | Sale | Smith Hunter C | Chief Financial Officer | 3,381 0.0052% | $106.06 | $358,599 | -8.97% | |
| 2026-02-04 | Sale | Smith Hunter C | Chief Financial Officer | 3,247 0.0048% | $105.99 | $344,145 | -12.07% | |
| 2025-12-11 | Sale | Cramer Pamela J. | Chief Human Resources Officer | 3,350 0.0047% | $111.00 | $371,850 | -13.80% | |
| 2025-11-20 | Sale | Cramer Pamela J. | Chief Human Resources Officer | 3,350 0.0052% | $105.00 | $351,750 | +1.43% | |
| 2025-11-10 | Sale | Cramer Pamela J. | Chief Human Resources Officer | 3,515 0.0053% | $100.00 | $351,500 | +4.10% | |
| 2025-11-07 | Sale | Cramer Pamela J. | Chief Human Resources Officer | 19,351 0.0253% | $98.82 | $1.91M | +1.31% | |
| 2025-10-30 | Sale | Shulman Joseph | Chief Technical Officer | 9,748 0.0155% | $115.24 | $1.12M | -9.12% |
| Smith Hunter C | Chief Financial Officer | 114024 0.1662% | $11.71M | 0 | 28 | |
| Mazabraud Yann | EVP, Head of International | 55655 0.0811% | $5.72M | 0 | 10 | |
| Cramer Pamela J. | Chief Human Resources Officer | 20814 0.0303% | $2.14M | 0 | 25 | |
| Shulman Joseph | Chief Technical Officer | 15915 0.0232% | $1.64M | 0 | 31 | |
| TETRAULT LYNN A. | director | 7000 0.0102% | $719,180.00 | 0 | 5 | |
| Garfield Alastair | Chief Scientific Officer | 2295 0.0033% | $235,788.30 | 0 | 2 | |
| German Christopher Paul | Corporate Controller & CAO | 0 0% | $0 | 0 | 8 | |
| Lee Jennifer Kayden | EVP, Head of North America | 0 0% | $0 | 0 | 24 | |
| BARRIS PETER J | 10 percent owner | 4909956 7.158% | $504.45M | 1 | 0 | +9.57% |
| BARRETT M JAMES | 10 percent owner | 4909956 7.158% | $504.45M | 1 | 0 | +9.57% |
| MOTT DAVID M | 10 percent owner | 4909956 7.158% | $504.45M | 1 | 0 | +9.57% |
| KERINS PATRICK J | 10 percent owner | 4909956 7.158% | $504.45M | 1 | 0 | +9.57% |
| SANDELL SCOTT D | 10 percent owner | 4909956 7.158% | $504.45M | 1 | 0 | +9.57% |
| BASKETT FOREST | 10 percent owner | 4909956 7.158% | $504.45M | 1 | 0 | +9.57% |
| NEW ENTERPRISE ASSOCIATES 13 LP | 10 percent owner | 4909956 7.158% | $504.45M | 1 | 0 | +9.57% |
| Viswanathan Ravi | 10 percent owner | 4909956 7.158% | $504.45M | 1 | 0 | +9.57% |
| RA CAPITAL MANAGEMENT, L.P. | 4360860 6.3575% | $448.03M | 0 | 8 | ||
| ORBIMED ADVISORS LLC | 10 percent owner | 2750079 4.0092% | $282.54M | 1 | 3 | +9.57% |
| MPM BIOVENTURES V, L.P. | 10 percent owner | 2696392 3.931% | $277.03M | 1 | 0 | +9.57% |
| BAKER BROS. ADVISORS LP | 1878242 2.7382% | $192.97M | 1 | 0 | <0.0001% | |
| PFIZER INC | 10 percent owner | 1427639 2.0813% | $146.68M | 1 | 0 | +9.57% |
| Foley Todd | director | 909258 1.3256% | $93.42M | 1 | 44 | +9.57% |
| Ipsen, S.A. | 10 percent owner | 833099 1.2145% | $85.59M | 1 | 0 | +9.57% |
| Gottesdiener Keith Michael | CEO & President | 506342 0.7382% | $52.02M | 0 | 15 | |
| Flynn James E | 10 percent owner | 468505 0.683% | $48.13M | 1 | 0 | +9.57% |
| Meeker David P | President and CEO | 201825 0.2942% | $20.74M | 2 | 5 | <0.0001% |
| Desikan Nithya | Chief Commercial Officer | 43602 0.0636% | $4.48M | 0 | 2 | |
| Van der Ploeg Leonardus H.T. | Chief Scientific Officer | 42339 0.0617% | $4.35M | 0 | 7 | |
| Roberts William T. | Chief Accounting Officer | 7872 0.0115% | $808,769.28 | 0 | 3 | |
| MCGIRR DAVID W J | director | 3000 0.0044% | $308,220.00 | 0 | 1 | |
| GOOD JENNIFER L | director | 3000 0.0044% | $308,220.00 | 0 | 3 |
$224,662,742 | 52 | 32.03% | $6.15B | |
$11,583,737 | 45 | 49.75% | $6.07B | |
$104,428,685 | 44 | 22.55% | $6.11B | |
$477,065,869 | 34 | 82.05% | $8.1B | |
$5,066,938 | 27 | 26.38% | $5.78B | |
Rhythm Pharmaceuticals, Inc. (RYTM) | $103,944,213 | 17 | 5.95% | $7.05B |
$11,859,102 | 17 | 18.62% | $9.05B | |
$57,686,748 | 13 | 21.11% | $5.78B | |
$762,720 | 11 | 52.96% | $9.65B | |
$2,477,801 | 11 | 4.98% | $7.73B | |
$45,831,857 | 11 | 83.04% | $5.94B | |
$35,908,794 | 10 | 126.31% | $9.37B | |
$25,064,843 | 9 | 12.75% | $6.63B | |
$55,713,031 | 8 | -0.36% | $8.46B | |
$2,246,813 | 6 | 70.15% | $8.57B | |
$41,376,000 | 4 | -12.07% | $8.83B | |
$142,493,653 | 3 | 4.30% | $5.94B | |
$50,990,767 | 2 | 19.79% | $8.36B | |
$7,600,000 | 1 | -4.05% | $6.59B |
| Increased Positions | 164 | +56.36% | 8M | +11.7% |
| Decreased Positions | 132 | -45.36% | 6M | -8.63% |
| New Positions | 57 | New | 1M | New |
| Sold Out Positions | 42 | Sold Out | 2M | Sold Out |
| Total Postitions | 323 | +11% | 73M | +3.06% |
| Blackrock, Inc. | $661,796.00 | 9.41% | 6.3M | +34,677 | +0.55% | 2025-09-30 |
| Ra Capital Management, L.P. | $596,600.00 | 8.48% | 5.68M | +120,000 | +2.16% | 2025-09-30 |
| Baker Bros. Advisors Lp | $588,527.00 | 8.37% | 5.6M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $524,675.00 | 7.46% | 5M | +1M | +39.21% | 2025-09-30 |
| Primecap Management Co/Ca/ | $447,643.00 | 6.36% | 4.26M | -615,178 | -12.61% | 2025-09-30 |
| Nea Management Company, Llc | $305,574.00 | 4.34% | 2.91M | 0 | 0% | 2025-09-30 |
| Perceptive Advisors Llc | $256,116.00 | 3.64% | 2.44M | +20,670 | +0.85% | 2025-09-30 |
| Fmr Llc | $225,266.00 | 3.2% | 2.15M | +191,742 | +9.82% | 2025-09-30 |
| State Street Corp | $213,029.00 | 3.03% | 2.03M | +121,050 | +6.35% | 2025-09-30 |
| Goldman Sachs Group Inc | $198,854.00 | 2.83% | 1.89M | +159,941 | +9.22% | 2025-09-30 |